TrialStem cells translational medicine2025

A single-center, phase 1/2a trial of hESC-derived mesenchymal stem cells (MR-MC-01) for safety and efficacy in interstitial cystitis patients.

Yoon Soo Kyung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.